Richard Godfrey

May 19, 2020

BerGenBio ASA: Results for the First Quarter 2020

May 08, 2019

BerGenBio ASA: Results for the First Quarter 2019

Nov 13, 2018

BerGenBio ASA: Results for the Third Quarter 2018

Nov 06, 2018

BerGenBio Reports ~80% Improvement in PFS of AXL-positive vs AXL-negative NSCLC Patients in Bemcentinib + KEYTRUDA PhII Combination Trial

Sep 25, 2018

BerGenBio: Updated PhII Clinical Data With Selective AXL Inhibitor Bemcentinib Strengthens its Potential to Improve NSCLC Patient Outcomes

May 15, 2018

BerGenBio ASA: Results for the First Quarter 2018

Feb 19, 2018

BerGenBio Completes Recruitment Into First Stage of Phase II Breast Cancer Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®

Feb 13, 2018

BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017

Jan 09, 2018

BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC